Education
About Us
Working with TipRanks
Follow Us
Siemens Healthineers AG Unsponsored ADR (SMMNY)
OTHER OTC:SMMNY
Top Page
Siemens Healthineers AG Unsponsored ADR
(OTC:SMMNY)
Select Model
Select Model
Rating:79Outperform
Price Target:
$32.00
▲(11.19% Upside)
Siemens Healthineers AG's strong financial performance and positive earnings call sentiment are the primary drivers of its stock score. The company's robust revenue growth, margin expansion, and strategic advancements outweigh the moderate valuation and neutral technical indicators. Challenges such as tariff impacts and market issues in China are notable but do not significantly detract from the overall positive outlook.
Siemens Healthineers AG Unsponsored ADR (SMMNY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$62.84B
Dividend Yield1.84%
Average Volume (3M)5.73K
Price to Earnings (P/E)26.4
Beta (1Y)0.97
Revenue Growth6.49%
EPS Growth17.05%
CountryUS
Employees72,000
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.37
Shares Outstanding2,256,000,000
10 Day Avg. Volume4,563
30 Day Avg. Volume5,726
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.24
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering0
Siemens Healthineers AG Unsponsored ADR Business Overview & Revenue Model
Company DescriptionSiemens Healthineers AG Unsponsored ADR (SMMNY) is a global leader in medical technology and healthcare solutions, providing innovative and high-quality products and services in the fields of imaging, diagnostics, and digital health. The company operates primarily in the healthcare sector, focusing on areas such as imaging systems (including MRI, CT, and ultrasound), laboratory diagnostics, and advanced therapies. Siemens Healthineers aims to enhance patient care by delivering cutting-edge technologies and solutions that improve clinical outcomes and operational efficiency in healthcare settings.
How the Company Makes MoneySiemens Healthineers generates revenue through multiple key streams, primarily from the sale of medical devices and imaging equipment, along with diagnostic products and services. Their Imaging segment, which includes MRI, CT, and ultrasound systems, forms a significant portion of their revenue, driven by demand for advanced imaging solutions in hospitals and clinics. In addition to hardware sales, the company earns revenue through software solutions and digital health applications that enhance medical imaging and diagnostics. Furthermore, Siemens Healthineers provides maintenance services and support for its products, contributing to recurring revenue. The company also engages in strategic partnerships and collaborations with healthcare providers and technology firms, which can lead to joint ventures and co-development of new technologies, thereby expanding their market reach and boosting revenues.
Siemens Healthineers AG Unsponsored ADR Earnings Call Summary
Earnings Call Date:Jul 30, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Nov 05, 2025
Earnings Call Sentiment Positive
The earnings call reflected a strong performance in key segments like Imaging and Varian, with significant revenue and EPS growth, leading to a positive outlook revision. However, challenges such as tariff impacts and market issues in China were noted. Despite these challenges, the company's robust performance and strategic advancements contribute to a positive sentiment.Q3-2025 Updates
Positive Updates
Strong Revenue Growth
In Q3, Siemens Healthineers grew by 7.6% with all regions contributing positively. Adjusted EPS grew by 23% to EUR 0.64 per share, supported by strong margin expansion despite tariff impacts.
Imaging and Varian Performance
Imaging achieved impressive revenue growth of almost 12% with margins improving to 21%. Varian continued its growth path with 9% comparable revenue growth and a strong 18.8% margin recovery.
Successful Diagnostics Transformation
The Atellica franchise, part of the Diagnostics business, is growing double digits and accounts for 60% of core lab revenues. Margin expansion is on track despite a slightly negative growth.
Free Cash Flow and Deleveraging
Free cash flow was strong, enabling leverage to drop below 3x for the first time since the Varian acquisition.
Raised Outlook for Fiscal Year 2025
Due to strong performance and certainty on tariffs, Siemens Healthineers raised its outlook for fiscal year 2025, expecting revenue growth of 5.5% to 6% and adjusted EPS between EUR 2.30 and EUR 2.45.
Negative Updates
Tariff Headwinds
Siemens Healthineers faced roughly EUR 100 million in tariff headwinds in Q3, with expectations for EUR 200 million to EUR 250 million net impact on pretax profit for the fiscal year.
Challenges in the China Market
Revenue in China remained around EUR 620 million, with no sustained market recovery yet. Diagnostics faced a significant drag due to volume-based procurement in China.
Company Guidance
During the Siemens Healthineers Q3 2025 earnings call, the company reported a robust performance with a 7.6% growth in revenue across all regions and a significant 23% increase in adjusted EPS to EUR 0.64 per share. Despite a EUR 100 million headwind from tariffs, Siemens Healthineers achieved strong margin expansion, particularly in Imaging, which saw a nearly 12% revenue growth and a 21% margin. Varian also performed well with a 9% increase in comparable revenue and an 18.8% margin, marking a recovery from Q2. Advanced Therapies grew with a 10.5% margin, while Diagnostics saw a slight revenue decline but improved margins to 9.2%. The equipment book-to-bill ratio was solid at 1.09, and free cash flow remained strong, reducing the leverage factor below 3x for the first time since acquiring Varian. The company raised its fiscal year 2025 outlook, expecting revenue growth of 5.5% to 6% and adjusted EPS between EUR 2.30 and EUR 2.45, highlighting its resilience and strategic focus on innovation.Siemens Healthineers AG Unsponsored ADR Financial Statement Overview
Summary
Income Statement
85
Very Positive
Balance Sheet
78
Positive
Cash Flow
80
Positive
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 22.36B | 21.68B | 21.71B | 18.00B | 14.46B |
| Gross Profit | 8.47B | 7.71B | 8.14B | 6.95B | 5.58B |
| EBITDA | 4.22B | 3.78B | 4.26B | 3.52B | 2.84B |
| Net Income | 1.94B | 1.51B | 2.04B | 1.73B | 1.41B |
Balance Sheet | |||||
| Total Assets | 46.05B | 46.68B | 49.06B | 41.93B | 25.09B |
| Cash, Cash Equivalents and Short-Term Investments | 2.68B | 1.64B | 1.44B | 1.32B | 656.00M |
| Total Debt | 16.21B | 16.65B | 16.65B | 14.31B | 5.50B |
| Total Liabilities | 27.81B | 28.55B | 29.20B | 25.87B | 12.58B |
| Stockholders Equity | 18.20B | 18.08B | 19.84B | 16.04B | 12.50B |
Cash Flow | |||||
| Free Cash Flow | 1.77B | 971.00M | 1.40B | 2.11B | 1.25B |
| Operating Cash Flow | 2.47B | 1.81B | 2.26B | 2.78B | 1.80B |
| Investing Cash Flow | -666.00M | -1.07B | -868.00M | -14.14B | -1.91B |
| Financing Cash Flow | -1.30B | -380.00M | -1.40B | 11.99B | -126.00M |
Siemens Healthineers AG Unsponsored ADR Technical Analysis
Positive
28.78
Price Trends
27.78
Positive
27.48
Positive
27.40
Positive
Market Momentum
0.27
Negative
51.79
Neutral
55.78
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SMMNY, the sentiment is Positive. The current price of 28.78 is above the 20-day moving average (MA) of 28.11, above the 50-day MA of 27.78, and above the 200-day MA of 27.40, indicating a bullish trend. The MACD of 0.27 indicates Negative momentum. The RSI at 51.79 is Neutral, neither overbought nor oversold. The STOCH value of 55.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SMMNY.
Siemens Healthineers AG Unsponsored ADR Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | $62.84B | 26.43 | 11.75% | 1.84% | 6.49% | 17.05% | |
| ― | $149.02B | 53.79 | ― | ― | 21.62% | 54.80% | |
| ― | $216.57B | 15.83 | 30.62% | 1.89% | 6.37% | ― | |
| ― | $141.06B | 48.91 | 14.25% | 0.91% | 11.36% | -15.66% | |
| ― | $116.69B | 25.33 | 9.72% | 3.10% | 4.98% | 22.08% | |
| ― | $26.09B | ― | ― | 3.25% | -0.76% | -55.03% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
SMMNY
Siemens Healthineers AG Unsponsored ADR
28.17
2.21
8.51%
ABT
Abbott Laboratories
124.67
8.28
7.11%
BSX
Boston Scientific
100.57
16.95
20.27%
PHG
Koninklijke Philips
27.27
1.58
6.15%
MDT
Medtronic
90.97
3.77
4.32%
SYK
Stryker
368.98
5.13
1.41%
Siemens Healthineers AG Unsponsored ADR Corporate Events
Siemens Healthineers Reports Strong Q3 2025 Results
Jul 30, 2025
Siemens Healthineers AG, a leading company in the healthcare sector, specializes in medical technology and offers a wide range of products and services in imaging, diagnostics, and advanced therapies. The company is known for its innovative solutions that enhance patient care worldwide.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.